Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Jung Won Chun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1964-7501; OpenAlex author ID A5068271025. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 3 papers · 2025: 6 papers · 2026: 3 papers

Papers 19

  1. Impact of treatment sequence and dose response on outcomes in locally advanced pancreatic cancer treated with hypofractionated proton beam therapy using simult… First author DOI 10.1016/j.radonc.2025.111295↗
  2. Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-4517↗
  3. Prognostic Value and Longitudinal Dynamics of Multigene Circulating Tumor DNA in Advanced Pancreatic Cancer Treated with 5-Fluorouracil-Based Chemotherapy. First author DOI 10.3390/ijms27198668↗
  4. ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167625↗
  5. Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicente… Co-author DOI 10.1093/clinchem/hvaf066↗
  6. Effectiveness and cost analysis of liposomal irinotecan in patients with pancreatic adenocarcinoma: a multicenter real-world study. Co-author DOI 10.1177/17588359251370492↗
  7. Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospective Cohort Study. Co-author DOI 10.3390/cancers17050896↗
  8. Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC. Co-author DOI 10.3390/cancers17182988↗
  9. Loss of SLC25A20 in Pancreatic Adenocarcinoma Reversed the Tumor-Promoting Effects of a High-Fat Diet. Co-author DOI 10.7150/thno.114912↗
  10. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Co-author DOI 10.1111/cas.16104↗
  11. Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer. Co-author DOI 10.3389/fonc.2024.1510016↗
  12. The Trends and Outcomes of Initial Palliative Chemotherapy in Patients with Pancreatic Cancer in Korea Based on National Health Insurance Service Data. Co-author DOI 10.3390/jcm13113229↗
  13. Annotation-Efficient Deep Learning Model for Pancreatic Cancer Diagnosis and Classification Using CT Images: A Retrospective Diagnostic Study. First author DOI 10.3390/cancers15133392↗
  14. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.291↗
  15. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic a… Co-author DOI 10.1177/17588359221119539↗
  16. Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies. Co-author DOI 10.5009/gnl210166↗
  17. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching … Co-author DOI 10.1186/s12885-021-08277-7↗
  18. Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach. Co-author DOI 10.5306/wjco.v11.i9.747↗
  19. The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case-control study in a Korean nationwide cohort. Co-author DOI 10.1002/cam4.2617↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sang Myung Woo · 14 shared papers, 2022–2026 · strength 2.93
  2. Woo Jin Lee · 11 shared papers, 2022–2026 · strength 2.43
  3. Sun‐Young Kong · 6 shared papers, 2023–2026 · strength 1.29
  4. Sung‐Sik Han · 5 shared papers, 2023–2026 · strength 1.07
  5. Sang Hyub Lee · 7 shared papers, 2019–2025 · strength 1.06
  6. Yun‐Hee Kim · 5 shared papers, 2023–2025 · strength 0.99
  7. Jin‐Hyeok Hwang · 4 shared papers, 2024–2025 · strength 0.90
  8. Woo Hyun Paik · 6 shared papers, 2019–2025 · strength 0.85
  9. Ji Kon Ryu · 6 shared papers, 2019–2025 · strength 0.85
  10. Yong‐Tae Kim · 6 shared papers, 2019–2025 · strength 0.85
  11. Sang‐Jae Park · 4 shared papers, 2023–2025 · strength 0.80
  12. Dong Kee Jang · 3 shared papers, 2024–2025 · strength 0.68
  13. Young Ae Kim · 3 shared papers, 2024–2025 · strength 0.68
  14. Yoon Suk Lee · 3 shared papers, 2024–2025 · strength 0.68
  15. Soo‐Youl Kim · 3 shared papers, 2025–2026 · strength 0.67
  16. In Rae Cho · 3 shared papers, 2021–2025 · strength 0.48
  17. Jong-Chan Lee · 2 shared papers, 2024–2025 · strength 0.46
  18. Hyeong Min Park · 2 shared papers, 2025 · strength 0.45
  19. Mi Rim Lee · 2 shared papers, 2024–2025 · strength 0.41
  20. Min Kyeong Kim · 2 shared papers, 2024–2025 · strength 0.41
  21. Min Kyu Jung · 2 shared papers, 2023–2025 · strength 0.40
  22. Gunn Huh · 3 shared papers, 2019–2021 · strength 0.36
  23. Gi Yeon Lee · 1 shared paper, 2026 · strength 0.30
  24. Changhoon Yoo · 1 shared paper, 2026 · strength 0.30
  25. Tae Hyun Kim · 1 shared paper, 2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.